C 2019

Therapeutic Use of Bioengineered Materials for Myocardial Infarction

SEDLÁKOVÁ, Veronika, Marc RUEL a Erik SUURONEN

Základní údaje

Originální název

Therapeutic Use of Bioengineered Materials for Myocardial Infarction

Autoři

SEDLÁKOVÁ, Veronika, Marc RUEL a Erik SUURONEN

Vydání

Cham, Nanoengineering Materials for Biomedical Uses, od s. 161-193, 33 s. 1. 2019

Nakladatel

Springer

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

30400 3.4 Medical biotechnology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Odkazy

Organizační jednotka

Lékařská fakulta

ISBN

978-3-030-31260-2

Klíčová slova anglicky

Regenerative Medicine Tissue Engineering Biomimetic Composites Nanomaterials for Biomedicine Biocompatible Nanomaterials Engineering of Materials for Biocompatibility Nanostructures for Repair Heart Tissue Regeneration

Štítky

Změněno: 26. 1. 2022 12:44, MUDr. Veronika Sedláková, Ph.D.

Anotace

V originále

Cardiovascular disease is a leading cause of worldwide mortality. Despite the success of current therapies for acute myocardial infarction (MI), many patients still suffer irreversible damage, and the prevalence of heart failure is growing. After MI, the extracellular matrix (ECM) of the damaged myocardium is modified to produce scar tissue. This remodeling reduces the efficacy of therapies and also hinders endogenous repair mechanisms. Therefore, a strategy to prevent adverse remodeling and provide a suitable ECM environment that supports cells, tissue repair and functional restoration may lead to a superior therapeutic outcome in MI patients. Bioengineered materials are an attractive approach for achieving this. Herein, we review current research on materials that can act as a biomimetic matrix for supporting cellular repair in the post-MI heart. We also examine how nanomaterials are being used to treat the damaged heart. Finally, we provide an overview of the breakthroughs and limitations of biomaterial therapies for cardiac repair.